



Theratechnologies Launches Direct-to-Consumer Campaigns for Trogarzo® and Egrifta® in the United States

June 20, 2019

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce the launch of two direct-to-consumer campaigns for TROGARZO® (ibalizumab-uiyk) for injection and EGRIFTA® (tesamorelin for injection), its FDA-approved products in the United States.